The definition of R1 is largely concordant to the corresponding level-of-evidence (LOE) in OncoKB (e.g., KRAS exons 2–4 mutations for anti-EGFR antibodies in advanced colorectal cancers). This evidence concerns the gene KRAS and colorectal cancer.